ClinicalTrials.gg
CompletedNCT05369208Updated Jun 3, 2026Results posted

Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITP

A Phase 3 interventional study of Avatrombopag Oral Tablet in Immune Thrombocytopenia, sponsored by Sobi, Inc.. Completed at 19 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Sobi, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 5 under way, 2 of them phase 3. avatrombopag · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
15th of 16
19 · median 53
Started
2022
the only one that year
Phase 3
6 of 16
1 open now
Registered
12th of 16
by date
Lead sponsor
4 of 16
Sobi, Inc.

Among the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 15th largest by enrollment, is the only one that started in 2022, is one of 6 in phase 3, and was the 12th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About avatrombopag

avatrombopag: first FDA approval 2018 (DOPTELET), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

Evaluate the efficacy, safety, and PK of avatrombopag given for 26 weeks in Japanese adults with chronic immune thrombocytopenia (ITP).

Read the detailed description

This Phase 3, multicenter, open label study will evaluate the efficacy, safety, and population pharmacokinetics (PK) of avatrombopag in Japanese adults with chronic ITP. At least 19 subjects will be enrolled. The study will consist of 3 phases: Pre-enrollment, Primary Investigation, and Extension Phase until market authorization in Japan.

03

Conditions studied

  • Immune Thrombocytopenia

Keywords

  • ITP
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has a confirmed diagnosis of chronic immune thrombocytopenia (ITP) (≥12 months duration) and has had an insufficient response to a previous ITP treatment, in the opinion of the Investigator.
  • Subject has an average of 2 counts \<30×10\^9/L (no single count can be >35×10\^9/L). The 2 samples must be obtained ≥48 hours and ≤2 weeks apart.

Exclusion criteria

Exclusion Criteria:

  • Subjects with known secondary immune thrombocytopenia (e.g., with known Helicobacter pylori-induced ITP, subjects infected with known (HIV) or virus (HCV) or subjects with known systemic lupus erythematosus).
  • Subjects with known inherited thrombocytopenia (e.g., Myosin Heavy Chain 9 (MYH-9) disorders) or hereditary thrombophilic disorders (e.g., Factor V Leiden, antithrombin III deficiency).
  • History of myelodysplastic syndrome (MDS).
  • History of arterial or venous thrombosis.
  • Subjects with a history of significant cardiovascular disease (e.g., congestive heart failure (CHF) Grade III/IV, arrhythmia known to increase the risk of thromboembolic events [e.g., atrial fibrillation], angina, coronary artery stent placement, angioplasty, coronary artery bypass grafting).
  • Subjects with a history of cirrhosis, portal hypertension, or chronic active hepatitis.
  • Subjects with concurrent malignant disease or receiving cytotoxic chemotherapy for a reason other than ITP treatment.
  • Use of immunoglobulins (IVIg and anti-D) or rescue therapy within 1 week of Day 1/Baseline.
  • Splenectomy or use of rituximab within 12 weeks of Day 1/Baseline.
  • Use of romiplostim or eltrombopag within 1 week of Day 1/Baseline.
  • Use of chronic corticosteroid treatment or azathioprine within 4 weeks of Day 1/Baseline, unless receiving a stable dose for at least 4 weeks.
  • Use of mycophenolate mofetil, cyclosporin A, or danazol within 4 weeks of Day 1/Baseline, unless receiving a stable dose for at least 12 weeks.
  • Use of cyclophosphamide or vinca alkaloid regimens within 4 weeks of Baseline Visit.
  • Currently receiving moderate or strong dual inhibitors/inducers of CYP2C9 and .
  • Serum creatinine ≥1.5× the (ULN).
  • Serum ≥2×ULN.
  • (ALT) or aspartate aminotransferase (AST) ≥3×ULN.
  • Females who are pregnant (positive beta-human chorionic gonadotropin (β-hCG) test) or breastfeeding.
  • Received treatment with an drug within 30 days or 5 half-lives (whichever is longer) before Day 1/Baseline.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Other
    Avatrombopag

    Avatrombopag 20 mg oral tablet

    Drug: Avatrombopag Oral Tablet

Interventions

  • Avatrombopag 20 mg given once daily (initial dose). Dosage adjustments were determined by the physician to maintain a platelet count between 50 x 10\^9 to 200 x 10\^9 as defined in the protocol and in accordance with overseas labeling.

    Also known as: Doptelet

06

What researchers measure

Primary outcomes

  1. Cumulative Number of Weeks of Platelet Response

    Cumulative number of weeks in which the platelet count is ≥50×10\^9/L during 26 weeks of treatment in the absence of rescue therapy.

    Time frame: 26 weeks of active treatment

Secondary outcomes

  1. Response Rate at Day 8

    Proportion of subjects with a platelet response ≥50×10\^9/L at Day 8 in the absence of rescue therapy

    Time frame: Day 8

07

Results

Posted Feb 11, 2025

Participant flow

Core Phase
Participant flow — Core Phase
MilestoneAvatrombopag
Started19
Completed15
Not completed4
Withdrew: Prohibited medication required2
Withdrew: Adverse event1
Withdrew: Lack of efficacy1
Extension Phase
Participant flow — Extension Phase
MilestoneAvatrombopag
Started15
Completed10
Not completed5
Withdrew: Lack of efficacy1
Withdrew: Physician decision1
Withdrew: Significant medical condition1
Withdrew: Required prohibited medication2

Outcome measures

PrimaryCumulative Number of Weeks of Platelet Response

Cumulative number of weeks in which the platelet count is ≥50×10\^9/L during 26 weeks of treatment in the absence of rescue therapy.

Time frame:
26 weeks of active treatment
Reported as:
Mean · cumulative number of weeks
Cumulative Number of Weeks of Platelet Response
cumulative number of weeksAvatrombopag
Cumulative Number of Weeks of Platelet Response13.47 ± 9.002
SecondaryResponse Rate at Day 8

Proportion of subjects with a platelet response ≥50×10\^9/L at Day 8 in the absence of rescue therapy

Time frame:
Day 8
Reported as:
Count of participants · Participants
Response Rate at Day 8
ParticipantsAvatrombopag
Response Rate at Day 812

Adverse events

Collected over Up to 26 weeks of treatment and a 4 week follow up period (Core Phase). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Avatrombopag0/19 (0%)3/19 (15.8%)18/19 (94.7%)
Most frequent serious events
Most frequent serious events
EventAvatrombopag
Autoimmune HepatitisHepatobiliary disorders1/19
Diffuse Large B-Cell LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/19
Heavy Menstrual BleedingReproductive system and breast disorders1/19
Most frequent other events
Showing 10 of 34
Most frequent other events
EventAvatrombopag
COVID-19Infections and infestations3/19
Upper Respiratory Tract InfectionInfections and infestations3/19
NauseaGastrointestinal disorders2/19
NasopharyngitisInfections and infestations2/19
UrticariaSkin and subcutaneous tissue disorders2/19
AnaemiaBlood and lymphatic system disorders1/19
LeukocytosisBlood and lymphatic system disorders1/19
PalpitationsCardiac disorders1/19
CushingoidEndocrine disorders1/19
Scleral HaemorrhageEye disorders1/19

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Avatrombopag
<=18 years0
Between 18 and 65 years12
>=65 years7
Age, Continuous
Age, Continuous(years)Avatrombopag
Mean56.0 ± 16.70
Sex: Female, Male
Sex: Female, Male(Participants)Avatrombopag
Female15
Male4
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Avatrombopag
American Indian or Alaska Native0
Asian19
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Avatrombopag
Japan19
08

Study locations

19 sites
  • Sobi Site 105
    Toyohashi, Aichi-ken 441-8570, Japan
  • Sobi Site 110
    Tōon, Ehime 791-0295, Japan
  • Sobi Site 118
    Iizuka-shi, Fukuoka 820-8505, Japan
  • Sobi Site 116
    Kitakyushu, Fukuoka 802-8555, Japan
  • Sobi Site 117
    Kurume, Fukuoka 830-8543, Japan
  • Sobi Site 114
    Gifu, Gifu 500-8513, Japan
  • Sobi Site 115
    Fukuyama-shi, Hiroshima 720-2121, Japan
  • Sobi Site 109
    Hiroshima, Hiroshima 730-0052, Japan
  • Sobi Site 108
    Kobe, Hyōgo 650-0047, Japan
  • Sobi Site 113
    Kanazawa, Ishikawa-ken 920-8650, Japan
  • Sobi Site 101
    Shiwa-gun, Iwata 028-3695, Japan
  • Sobi Site 111
    Fujisawa, Kanagawa 251-8550, Japan
  • Sobi Site 119
    Kumamoto, Kumamoto 862-8655, Japan
  • Sobi Site 107
    Hirakata, Osaka 573-1191, Japan
  • Sobi Site 106
    Suita, Osaka 565-0871, Japan
  • Sobi Site 104
    Hachiōji-shi, Tokyo 192-0032, Japan
  • Sobi Site 103
    Bunkyō City, Toyko 113-8603, Japan
  • Sobi Site 102
    Chuo-shi, Yamanashi 409-3898, Japan
  • Sobi Site 112
    Kofu, Yamanashi 400-8506, Japan
09

References and documents

Publications

  • Yamaguchi H, Iino M, Tomiyama Y, Kamiya H, Zhang J, Skuban N. (2025, October 10-12). One-year efficacy and safety of avatrombopag for chronic immune thrombocytopenia in Japanese adults [Conference presentation abstract]. 87th Annual Meeting of the Japanese Society of Hematology, Kobe, Hyogo, Japan.
  • Yamaguchi H, Iino M, Kowata S, Yamamoto R, Yamanouchi J, Imamura Y, Kirito K, Yokoyama K, Ito T, Ishikawa T, Shiratsuchi M, Tomiyama Y, Kamiya H, Zhang J, Jamieson BD. Correction: A phase 3 study of the efficacy and safety of avatrombopag in Japanese adults with chronic immune thrombocytopenia. Int J Hematol. 2025 Oct;122(4):623. doi: 10.1007/s12185-025-04054-5. No abstract available. PubMed 40828490 ↗
  • Yamaguchi H, Iino M, Kowata S, Yamamoto R, Yamanouchi J, Imamura Y, Kirito K, Yokoyama K, Ito T, Ishikawa T, Shiratsuchi M, Tomiyama Y, Kamiya H, Zhang J, Jamieson BD. A phase 3 study of the efficacy and safety of avatrombopag in Japanese adults with chronic immune thrombocytopenia. Int J Hematol. 2025 Oct;122(4):521-532. doi: 10.1007/s12185-025-04001-4. Epub 2025 May 20. PubMed 40392465 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Jan 2024, 19 months.

Results were first posted in Feb 2025, 1 year after primary completion.

Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's 19 months is below that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2022
First posted
May 11, 2022
StartActual
Jun 15, 2022
Primary completionActual
Jan 17, 2024
CompletionActual
Oct 29, 2025
Results first posted
Feb 11, 2025
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05369208
Lead sponsor
Sobi, Inc.
Responsible party
Sponsor
First posted
May 11, 2022
Start date
Jun 15, 2022
Primary completion
Jan 17, 2024
Completion
Oct 29, 2025
Results posted
Feb 11, 2025
Last update
Jun 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avatrombopag

Start the discussion